MLL translocation in two castration-resistant prostate cancer patients

被引：0
作者：
Chowdry, Rajasree Pia [1 ]
Ledet, Elisa [2 ]
Asinghe, Lahiru Ran. [3 ]
Sartor, Alton Oliver [2 ]
机构：
[1] Tulane Univ, Sect Hematol Med Oncol, Hematol Oncol, New Orleans, LA USA
[2] Tulane Canc Ctr, Dept Urol, New Orleans, LA USA
[3] Tulane Univ, Sch Med, New Orleans, LA 70112 USA
来源：
CANADIAN JOURNAL OF UROLOGY | 2016年 / 23卷 / 05期
关键词：
prostate cancer; castration-resistant; MLL; bone marrow; FUSION PROTEINS; MENIN; LEUKEMIA;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The mixed-lineage leukemia (MLL) protein acts as a histone methyltransferase regulating multiple genetic elements. Rearrangements of the MLL gene result in expression of MLL fusion proteins that occur in some acute leukemias and are associated with poor prognosis. The MLL protein complex has been shown to interact with the androgen receptor via the MLL-menin subunit, thus promoting gene activation. The presence of MLL translocation has not been previously reported in patients with castrate resistant prostate cancer (CRPC). We describe two cases of metastatic CRPC with a translocation in the MLL gene detected by a specific fluorescent in situ hybridization (FISH) assay. Both patients had an aggressive course and succumbed to the illness.
引用
收藏
页码：8483 / 8486
页数：4
相关论文
共 50 条
[41]   Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer [J].
Wang, J. ;
McGuire, T. R. ;
Britton, H. C. ;
Schwarz, J. K. ;
Loberiza, F. R., Jr. ;
Meza, J. L. ;
Talmadge, J. E. .
CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (02) :111-124
[42]   Management of Bone Metastases fin Patients with Castration-Resistant Prostate Cancer [J].
Cathomas, Richard ;
Bajory, Zoltan ;
Bouzid, Mounira ;
El Ghoneimy, Ahmed ;
Gillessen, Silke ;
Goncalves, Frederico ;
Kacso, Gabriel ;
Kramer, Gero ;
Milecki, Piotr ;
Pacik, Dalibor ;
Tantawy, Wahid ;
Lesniewski-Kmak, Krzystof .
UROLOGIA INTERNATIONALIS, 2014, 92 (04) :377-386
[43]   Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer [J].
Maines, Francesca ;
Caffo, Orazio ;
Veccia, Antonello ;
Trentin, Chiara ;
Tortora, Giampaolo ;
Galligioni, Enzo ;
Bria, Emilio .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (03) :498-506
[44]   Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer [J].
Ben Toumia, Imene ;
Ponassi, Marco ;
Barboro, Paola ;
Iervasi, Erika ;
Vargas, Gabriela Coronel ;
Banelli, Barbara ;
Fiordoro, Stefano ;
Ghedira, Leila Chekir ;
Kohnke, Franz Heinrich ;
Izzotti, Alberto ;
Rosano, Camillo .
INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) :1185-1193
[45]   Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer [J].
Imene Ben Toumia ;
Marco Ponassi ;
Paola Barboro ;
Erika Iervasi ;
Gabriela Coronel Vargas ;
Barbara Banelli ;
Stefano Fiordoro ;
Leila Chekir Ghedira ;
Franz Heinrich Kohnke ;
Alberto Izzotti ;
Camillo Rosano .
Investigational New Drugs, 2022, 40 :1185-1193
[46]   Abiraterone in the treatment of metastatic castration-resistant prostate cancer [J].
Mostaghel, Elahe A. .
CANCER MANAGEMENT AND RESEARCH, 2014, 6 :39-51
[47]   Novel Strategies for Treating Castration-Resistant Prostate Cancer [J].
Leung, David Ka-Wai ;
Chiu, Peter Ka-Fung ;
Ng, Chi-Fai ;
Teoh, Jeremy Yuen-Chun .
BIOMEDICINES, 2021, 9 (04)
[48]   JNK promotes the progression of castration-resistant prostate cancer [J].
Feng, Yigeng ;
Cao, Hongwen ;
Wang, Dan ;
Chen, Lei ;
Gao, Renjie ;
Sun, Peng .
ACTA BIOCHIMICA POLONICA, 2023, 70 (04) :817-822
[49]   Mechanisms of resistance in castration-resistant prostate cancer (CRPC) [J].
Chandrasekar, Thenappan ;
Yang, Joy C. ;
Gao, Allen C. ;
Evans, Christopher P. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) :365-380
[50]   Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer [J].
Lee, Patrick ;
Aragon-Ching, Jeanny B. .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (10) :1040-1045
12345